Relugolix + P Gp Inhibitors (Oral) Interaction
Majorinteraction on record
Description
Co-administration increases relugolix exposure and risk of adverse reactions. If unavoidable, separate dosing by at least 6 hours and monitor frequently.
Mechanism
Relugolix is a P-gp substrate; P-gp inhibition increases relugolix exposure
Source: NLP:relugolix